The beginning of the end: What is the future of interferon therapy for chronic hepatitis C?

Feld, Jordan J.

doi:10.1016/j.antiviral.2014.02.005

Cited by 28 publications

(18 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The optimal combination of DAAs (and/or HTAs) that maximizes potency, minimizes resistance, and limits toxicity will be available soon [100] . Once combination DAA therapies are available, peginterferon will serve a smaller and smaller role [101] . Indeed, DAAs trump interferon-alpha in their capacity to rescue exhausted T cells upon HCV clearance [102] .…”

Section: Treatmentmentioning

confidence: 99%

Hepatitis C virus: Virology, diagnosis and treatment

2015

WJH

162

114

View full text Add to dashboard Cite

More than twenty years of study has provided a better understanding of hepatitis C virus (HCV) life cycle, including the general properties of viral RNA and proteins. This effort facilitates the development of sensitive diagnostic tools and effective antiviral treatments. At present, serologic screening test is recommended to perform on individuals in the high risk groups and nucleic acid tests are recommended to confirm the active HCV infections. Quantization and genotyping of HCV RNAs are important to determine the optimal duration of anti-viral therapy and predict the likelihood of response. In the early 2000s, pegylated interferon plus ribavirin became the standard anti-HCV treatment. However, this therapy is not ideal. To 2014, boceprevir, telaprevir, simeprevir, sofosbuvir and Harvoni are approved by Food and Drug Administration for the treat of HCV infections. It is likely that the new all-oral, interferon-free, pan-genotyping anti-HCV therapy will be available within the next few years. Majority of HCV infections will be cured by these antiviral treatments. However, not all patients are expected to be cured due to viral resistance and the high cost of antiviral treatments. Thus, an efficient prophylactic vaccine will be the next challenge in the fight against HCV infection. Core tip: Understanding the general properties of hepatitis C virus (HCV) viral RNA and proteins facilitates the development of sensitive diagnostic tools and effective antiviral treatments. At present, serologic screening test is recommended to perform on individuals in the high risk groups and nucleic acid tests are recommended to confirm the active HCV infections. To 2014, in addition to pegylated interferon and ribavirin, boceprevir, telaprevir, simeprevir, sofosbuvir and Harvoni are approved by Food and Drug Administration to treat HCV infections. The majority of HCV infections can be cured by these anti-viral treatments. An efficient prophylactic vaccine will be the next challenge in the fight against HCV infection. REVIEWSubmit a

show abstract

Section: Treatmentmentioning

confidence: 99%

Hepatitis C virus: Virology, diagnosis and treatment

2015

WJH

162

114

View full text Add to dashboard Cite

show abstract

“…The most effective antiviral therapy until the last year consisted of subcutaneous injections of long-acting pegylated interferon-α 2a or 2b (PEG-IFN) combined with oral treatment with ribavirin (RBV). Advances in the understanding of the HCV lifecycle have led to the development of numerous highly effective, welltolerated oral direct-acting antivirals (DAAs) (Feld 2014). The disadvantages of the antiviral regimen of pegylated interferon and ribavirin is difficult to tolerate (Fried 2002), expensive, requires up to 48 weeks of treatment, and cures only 40-60% of a very highly selected group of patients (McHutchison, Gordon, et al 1998).…”

Section: Introductionmentioning

confidence: 99%

“…The disadvantages of the antiviral regimen of pegylated interferon and ribavirin is difficult to tolerate (Fried 2002), expensive, requires up to 48 weeks of treatment, and cures only 40-60% of a very highly selected group of patients (McHutchison, Gordon, et al 1998). DAAs therapy has the disadvantage that the impending arrival of multiple DAA regimens may drive the cost of therapy to become prohibitively expensive, and therefore not affordable to people in resource-poor settings (Feld 2014). Herbal supplements are frequently used in chronic HCV infection.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Silibinin Enriched Silymarin in Chronic HCV Patients

Hamed¹,

Khaled²,

Fathelbab³

et al. 2017

IAM

View full text Add to dashboard Cite

Background/ Aim: Silymarin is a polyphenolic compound with anti-hepatotoxic activity. It has low oral bioavailability due to its poor aqueous solubility. Thus enhancement of its dissolution may lead to a better bioavailability. The objective of the presented study was to prepare fast dissolving enriched silymarin preparation via the preparation of enriched silymarin as solid dispersion and compare it with Legalon capsules in chronic HCV patients in a clinical study. Method: Enriched silymarin solid dispersion was prepared in sufficient amount. A clinical study was conducted including 24 patients. The patients were divided into two groups; each group had 12 patients. One group received the solid dispersion. The second group received Legalon capsules. Patients received capsules 3 times daily for 12 weeks. All these patients had been subjected to full medical history, abdominal ultrasonography, laboratory investigations and quality of life assessment at baseline and after treatment. Results: Solid dispersion had significantly faster dissolution rate. It is effective in reducing AST, ALT, total bilirubin, improving prothrombin concentration, prothrombin time and quality of life. Conclusion: Silymarin solid dispersion is a promising preparation. Large scale and longer duration may be required to ascertain its effects.

show abstract

“…In the meantime, new DAA are approved [12] . Thus, a therapeutic hold is observed in the prospect of new treatment options promising no drug-drug interactions and less severe side effects, most importantly because interferon may become dispensable [13] . However, when and whether at all the first generation PIs will be replaced by novel DAAs also depends on economic aspects in a number of countries and potentially the emergence of resistances [14,15] .…”

Section: Introductionmentioning

confidence: 99%

Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant

Herzer¹

2015

WJH

View full text Add to dashboard Cite

AIM: To characterize management of telaprevir (TVR)-based triple therapy of hepatitis C virus (HCV) reinfection after liver transplantation (LT). METHODS:We retrospectively analyzed safety and efficacy of telaprevir -based triple therapy in a single center cohort of 19 patients with HCV genotype (GT) 1 recurrence after LT, with respect to factors possibly predicting sustained viral response (SVR) or non-SVR. All patients were treated with TVR, pegylated (PEG) and ribavirine (RBV) for 12 wk followed by a dual phase with PEG/RBV for 12 wk in 7 patients and for 36 wk in 5 patients. RESULTS:In total 11/19 (58%) of patients achieved a sustained response. All (11/11) SVR patients showed a rapid viral response at treatment weeks 4 and 11/14 rapid virological response (RVR) patients achieved SVR. Notably, all (7/7) patients who completed 48 wk of therapy and 80% (4/5) patients who completed Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant Retrospective Study ORIGINAL ARTICLE24 wk of therapy achieved SVR24. Treatment failure was significantly (P > 0.049) more frequent in GT1a infection (5/7) compared to GT1b (3/12) infection and was associated with emergence of resistance-associated mutations in the NS3 protease domain. Bilirubin level at baseline is also related to SVR (P > 0.030). None of the patients had to discontinue treatment due to side effects.CONCLUSION: RVR, GT and bilirubin are clearly related to achievement of SVR. Providing a thorough patient selection and monitoring, a full course of TVR-based triple therapy in LT patients is feasible and achieves high SVR rates.

show abstract

The beginning of the end: What is the future of interferon therapy for chronic hepatitis C?

Cited by 28 publications

References 50 publications

Hepatitis C virus: Virology, diagnosis and treatment

Hepatitis C virus: Virology, diagnosis and treatment

Evaluation of Silibinin Enriched Silymarin in Chronic HCV Patients

Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant

Contact Info

Product

Resources

About